Samumed has announced positive results from a Phase I trial of an inhalation solution of its novel Wnt signaling modulator SM04646, which the company is developing for the treatment of idiopathic pulmonary fibrosis (IPF).
The study enrolled 17 healthy subjects and delivered 4 ascending doses of SM04646 in a single inhalation via nebulizer. All doses were well tolerated, with no dose limiting toxicity or serious adverse events noted in any of the 4 treatment groups.
The company said that it would present more detailed results, including PK data, at upcoming medical conferences.
Read the Samumed press release.
